Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE:002773)

SHE:002773 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Cash & Equivalents	3,425	6,435	5,690	4,702	3,585	2,939
Trading Asset Securities	2,969	-	-	-	100	200
Cash & Short-Term Investments	6,394	6,435	5,690	4,702	3,685	3,139
Cash Growth	0.02%	13.11%	21.00%	27.59%	17.41%	-5.67%
Accounts Receivable	275.4	189.1	177.85	160.41	160.69	204.63
Other Receivables	10.12	37.31	21.67	19.04	27.88	43.59
Receivables	285.53	226.4	199.52	179.45	188.57	248.22
Inventory	413.19	407.05	386.86	403.61	330.96	295.62
Prepaid Expenses	-	1.64	-	-	-	-
Other Current Assets	141.76	13.93	12.93	20.41	24.22	15.89
Total Current Assets	7,235	7,084	6,289	5,306	4,229	3,699
Property, Plant & Equipment	2,138	2,253	2,353	2,411	2,553	2,097
Long-Term Investments	15.28	15.79	16.44	16.78	16.98	17.73
Other Intangible Assets	333.38	352.93	286.89	316.8	331.14	278.21
Long-Term Deferred Tax Assets	95.07	128.85	259.46	358.08	486.31	545.66
Long-Term Deferred Charges	189.27	61.76	123.24	99.33	70.47	84.67
Other Long-Term Assets	52.22	23.07	14.48	22.01	33.93	233.89
Total Assets	10,058	9,920	9,342	8,530	7,721	6,956

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Accounts Payable	159.74	221.43	297.16	344.03	409.54	343.13
Accrued Expenses	21.24	189.45	233.88	203.64	169.59	174.63
Current Portion of Leases	0.35	1.68	1.73	0.53	1.6	2.57
Current Income Taxes Payable	104.22	18.04	13.31	9.82	19.69	16.49
Current Unearned Revenue	4.5	2.06	8.92	5.1	9.14	8.39
Other Current Liabilities	328.99	169.05	99.98	91.31	84.1	122.16
Total Current Liabilities	619.03	601.72	654.99	654.43	693.66	667.37
Long-Term Leases	1.08	1.82	3.47	1.48	3.27	4.43
Long-Term Unearned Revenue	32.05	32.1	23.58	22.94	30.3	25.51
Long-Term Deferred Tax Liabilities	10.55	9.58	13.03	7.94	5.14	2.06
Other Long-Term Liabilities	-	-	-	30.96	81.48	151.71
Total Liabilities	662.71	645.22	695.07	717.76	813.85	851.08

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Common Stock	921.33	921.32	919.78	919.46	919.46	919.46
Additional Paid-In Capital	2,028	2,031	1,997	1,990	1,994	1,986
Retained Earnings	6,488	6,348	5,738	4,896	3,989	3,185
Comprehensive Income & Other	-3.2	-1.45	-1.33	-1.34	-1.05	-0.83
Total Common Equity	9,434	9,299	8,653	7,804	6,902	6,090
Minority Interest	-39.26	-24.27	-6.34	7.89	5.07	15.24
Shareholders' Equity	9,395	9,275	8,647	7,812	6,907	6,105
Total Liabilities & Equity	10,058	9,920	9,342	8,530	7,721	6,956

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Total Debt	1.42	3.51	5.2	2.01	4.87	7
Net Cash (Debt)	6,393	6,432	5,684	4,700	3,681	3,132
Net Cash Growth	0.06%	13.15%	20.94%	27.70%	17.52%	-5.88%
Net Cash Per Share	6.93	6.97	6.20	5.13	4.02	3.42
Filing Date Shares Outstanding	921.33	921.32	919.78	919.46	919.46	919.46
Total Common Shares Outstanding	921.33	921.32	919.78	919.46	919.46	919.46
Working Capital	6,616	6,483	5,634	4,651	3,535	3,031
Book Value Per Share	10.24	10.09	9.41	8.49	7.51	6.62
Tangible Book Value	9,101	8,946	8,366	7,487	6,571	5,812
Tangible Book Value Per Share	9.88	9.71	9.10	8.14	7.15	6.32
Buildings	-	2,111	2,126	1,989	1,785	1,137
Machinery	-	1,387	1,271	1,236	1,088	830.91
Construction In Progress	-	97.56	112.35	166.54	475.88	808.69

Data Source: S&P Global Market Intelligence Last updated: Oct 27, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 2, 2026

Data Sources Report a data error